Love T.
- Country
- Sweden
- Department
- Z97SE10003:Hematologiska Kliniken
Research Overview
- Persistence of Remission Following Discontinuation of BCMA-CD3 Bispecific Antibodies in Multiple Myeloma Patients With Major M-Spike Response
- Phase 3 Randomized Trial of Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, and Ciltacabtagene Autoleucel in Transplant-Eligible Multiple Myeloma
- Phase 3 Randomized Study of Elranatamab Versus Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem-Cell Transplantation
Data & Insights
Has run more than one trial at 59 of 129 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of multiple myeloma, focusing on innovative therapeutic approaches in hematologic malignancies.
- Novel combination therapies
- Immunotherapy applications
- Stem cell treatment protocols
Their research encompasses advanced treatment modalities integrating targeted therapies with established therapeutic protocols.
Cell-Based Therapies
The investigator demonstrates expertise in cellular therapy applications, particularly in blood cancers and immune system disorders.
- CAR-T cell therapy
- Autologous transplantation
- Cellular immunotherapy
Their work explores the integration of innovative cellular approaches with conventional treatment methods.
Treatment Optimization
The investigator focuses on developing optimized treatment strategies for hematologic conditions.
- Combination therapy protocols
- Response assessment methods
- Long-term disease management
Their expertise includes evaluation of therapeutic responses and development of maintenance strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.